Release form, composition and packing
Of white or nearly white, Valium, with a facet.
1 tab. betahistine dihydrochloride 8 mg.
Excipients: microcrystalline cellulose, mannitol, citric acid anhydrous, talc, Aerosil (colloidal silicon dioxide).
Of white or nearly white, Valium, Bevel and risks.
1 tab. betahistine dihydrochloride 16 mg.
Excipients: microcrystalline cellulose, mannitol, citric acid anhydrous, talc, Aerosil (colloidal silicon dioxide).
Clinico-pharmacological group: drug improving the microcirculation of the labyrinth that is used in the pathology of the vestibular apparatus.
Pharmacological action
Synthetic analogue of histamine. Betahistine acts primarily on the histamine H1-and H3-receptors in the inner ear and vestibular nuclei of the CNS. By direct agonistic effects on H1-receptors of vessels of the inner ear, as well as indirectly through effects on H3-receptors improves microcirculation and capillary permeability, normalizes blood pressure of the endolymph in the labyrinth and cochlea. However, betahistine increases blood flow to the basilar artery.
Possesses a strong central effect, as an inhibitor of H3-receptor nuclei vestibular nerve. Improves conductivity in the neurons of the vestibular nuclei at the brainstem. Clinical manifestation of these properties is to reduce the frequency and intensity of vertigo, tinnitus reduction, improvement of hearing in the case of his slides.
Pharmacokinetics
Absorption and distribution
After oral administration, rapidly absorbed from the gastrointestinal tract. Cmax plasma levels reached after 3 h.
Plasma protein binding is low.
Breeding
T1 / 2 - 3-4 hours almost completely excreted by the kidneys as metabolites (2-pyridylacetic acid) for 24 h.
Statement
treatment and prophylaxis of vestibular vertigo of various origins;
syndromes, which include dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere's disease or syndrome.
Dosing regimen
The drug is taken orally, during a meal. 8 mg tablets: 1-2 tablets. 3 times a day. Tablets 16 mg: 1 / 2 -1 tablet. 3 times a day. Improvement is usually noted at the beginning of therapy, a stable therapeutic effect occurs after 2 weeks of treatment and may increase within a few months of treatment. Treatment of long-term. The duration of the drug is selected individually.
Side effect
From the digestive system: gastrointestinal disorders.
Allergic reactions: itching, rash, urticaria, angioedema.
Contraindications
childhood and adolescence to 18 years (due to lack of data);
pregnancy;
lactation;
hypersensitivity to the drug.
With caution is prescribed for a stomach ulcer or duodenal ulcer (including history), pheochromocytoma, bronchial asthma. Of these patients should be regularly observed during the treatment period.
Pregnancy and lactation
Insufficient data to assess the safety and efficacy of the drug during pregnancy and lactation. In connection with this Asniton contraindicated in pregnancy.
If necessary, use during lactation breastfeeding at the time of treatment should be discontinued.
Cautions
During the period of treatment should regularly monitor the condition of patients with gastric ulcer or duodenal ulcer (including history), pheochromocytoma, bronchial asthma.
Effects on ability to drive vehicles and management mechanisms
Betahistine does not have a sedative effect and does not affect your ability to drive or engage in activities that require quickness of psychomotor reactions.
Overdose
Symptoms: nausea, vomiting, cramps.
Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.
Drug Interactions
Cases of interaction or incompatibility with other drugs is unknown.
Conditions and terms of
List B. The drug should be kept away from children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.
Of white or nearly white, Valium, with a facet.
1 tab. betahistine dihydrochloride 8 mg.
Excipients: microcrystalline cellulose, mannitol, citric acid anhydrous, talc, Aerosil (colloidal silicon dioxide).
Of white or nearly white, Valium, Bevel and risks.
1 tab. betahistine dihydrochloride 16 mg.
Excipients: microcrystalline cellulose, mannitol, citric acid anhydrous, talc, Aerosil (colloidal silicon dioxide).
Clinico-pharmacological group: drug improving the microcirculation of the labyrinth that is used in the pathology of the vestibular apparatus.
Pharmacological action
Synthetic analogue of histamine. Betahistine acts primarily on the histamine H1-and H3-receptors in the inner ear and vestibular nuclei of the CNS. By direct agonistic effects on H1-receptors of vessels of the inner ear, as well as indirectly through effects on H3-receptors improves microcirculation and capillary permeability, normalizes blood pressure of the endolymph in the labyrinth and cochlea. However, betahistine increases blood flow to the basilar artery.
Possesses a strong central effect, as an inhibitor of H3-receptor nuclei vestibular nerve. Improves conductivity in the neurons of the vestibular nuclei at the brainstem. Clinical manifestation of these properties is to reduce the frequency and intensity of vertigo, tinnitus reduction, improvement of hearing in the case of his slides.
Pharmacokinetics
Absorption and distribution
After oral administration, rapidly absorbed from the gastrointestinal tract. Cmax plasma levels reached after 3 h.
Plasma protein binding is low.
Breeding
T1 / 2 - 3-4 hours almost completely excreted by the kidneys as metabolites (2-pyridylacetic acid) for 24 h.
Statement
treatment and prophylaxis of vestibular vertigo of various origins;
syndromes, which include dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere's disease or syndrome.
Dosing regimen
The drug is taken orally, during a meal. 8 mg tablets: 1-2 tablets. 3 times a day. Tablets 16 mg: 1 / 2 -1 tablet. 3 times a day. Improvement is usually noted at the beginning of therapy, a stable therapeutic effect occurs after 2 weeks of treatment and may increase within a few months of treatment. Treatment of long-term. The duration of the drug is selected individually.
Side effect
From the digestive system: gastrointestinal disorders.
Allergic reactions: itching, rash, urticaria, angioedema.
Contraindications
childhood and adolescence to 18 years (due to lack of data);
pregnancy;
lactation;
hypersensitivity to the drug.
With caution is prescribed for a stomach ulcer or duodenal ulcer (including history), pheochromocytoma, bronchial asthma. Of these patients should be regularly observed during the treatment period.
Pregnancy and lactation
Insufficient data to assess the safety and efficacy of the drug during pregnancy and lactation. In connection with this Asniton contraindicated in pregnancy.
If necessary, use during lactation breastfeeding at the time of treatment should be discontinued.
Cautions
During the period of treatment should regularly monitor the condition of patients with gastric ulcer or duodenal ulcer (including history), pheochromocytoma, bronchial asthma.
Effects on ability to drive vehicles and management mechanisms
Betahistine does not have a sedative effect and does not affect your ability to drive or engage in activities that require quickness of psychomotor reactions.
Overdose
Symptoms: nausea, vomiting, cramps.
Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.
Drug Interactions
Cases of interaction or incompatibility with other drugs is unknown.
Conditions and terms of
List B. The drug should be kept away from children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.
No comments:
Post a Comment